Back to top
more

Scholar Rock (SRRK)

(Real Time Quote from BATS)

$28.07 USD

28.07
536,669

-1.01 (-3.47%)

Updated Nov 11, 2024 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -20.00% and 24.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q3 Earnings Expected to Decline

by Zacks Equity Research

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Scholar Rock Holding Corporation (SRRK) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -7.69% and -13.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q2 Earnings Expected to Decline

by Zacks Equity Research

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Scholar Rock Holding Corporation (SRRK) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -10.14% and -29.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q1 Earnings Expected to Decline

by Zacks Equity Research

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -27.42% and -53.27%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Scholar Rock Holding Corporation (SRRK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More

by Zacks Equity Research

Gilead (GILD) and Novavax (NVAX) continue to be in the spotlight on coronavirus-related updates.

Scholar Rock Holding Corporation (SRRK) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -22.64% and -40.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Scholar Rock Holding Corporation (SRRK) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -480.00% and -74.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Scholar Rock Holding Corporation (SRRK) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Scholar Rock Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Scholar Rock has been struggling lately, but the selling pressure may be coming to an end soon.

Is Scholar Rock Holding (SRRK) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (SRRK) Outperforming Other Medical Stocks This Year?

Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 31.58% and 38.95%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -77.42% and -62.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Scholar Rock Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Scholar Rock Holding.

Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review

by Zacks Equity Research

FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.

Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal

by Zacks Equity Research

It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.

Gilead Partners with Scholar Rock for Fibrotic Disease Drugs

by Zacks Equity Research

Gilead Sciences (GILD) collaborates with Scholar Rock Holding Corporation for the development of fibrotic disease candidates.

    Sarepta Announces Agreement With Lysogene for Gene Therapy

    by Zacks Equity Research

    Sarepta Therapeutics (SRPT) signs license agreement with France-based Lysogene to boost its gene therapy portfolio.

      Pfizer Discontinues Studies on DMD Candidate Domagrozumab

      by Zacks Equity Research

      Pfizer (PFE) terminates two clinical studies evaluating pipeline candidate, domagrozumab, in patients with duchenne muscular dystrophy.